# Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity
Canonical URL: https://biopharmsignal.com/news/GPCR/structure-therapeutics-announces-publication-in-nature-medicine-highlighting-phase-2b-access-program-of-aleniglipron-for-obesity
Ticker: GPCR
Company: Structure Therapeutics
Source: Structure Therapeutics
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.structuretx.com
## Summary

Publication presented concurrently with oral presentation at American Diabetes Association’s 86th Scientific Sessions from ACCESS development program with aleniglipron, a once-daily oral small molecule GLP-1 receptor agonist Publication and presentation detail dose-dependent, clinically meaningful

## Article Body
Publication presented concurrently with oral presentation at American Diabetes Association’s 86th Scientific Sessions from ACCESS development program with aleniglipron, a once-daily oral small molecule GLP-1 receptor agonist Publication and presentation detail dose-dependent, clinically meaningful
## Recent Company News
- 2026-06-25 13:46 EST — [Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity](https://biopharmsignal.com/news/GPCR/structure-therapeutics-announces-publication-in-nature-medicine-highlighting-phase-2b-access-program-of-aleniglipron-for-obesity) — Source: Structure Therapeutics
- 2026-06-25 13:46 EST — [Structure Therapeutics Announces Participation in Upcoming Investor Conferences](https://biopharmsignal.com/news/GPCR/structure-therapeutics-announces-participation-in-upcoming-investor-conferences) — Source: Structure Therapeutics
- 2026-06-25 13:46 EST — [Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights](https://biopharmsignal.com/news/GPCR/structure-therapeutics-reports-first-quarter-2026-financial-results-and-recent-highlights) — Source: Structure Therapeutics
- 2026-06-25 13:46 EST — [Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025](https://biopharmsignal.com/news/GPCR/structure-therapeutics-to-report-data-from-access-clinical-program-of-oral-small-molecule-glp-1-receptor-agonist-aleniglipron-on-december-8-2025) — Source: Structure Therapeutics
- 2026-06-25 13:46 EST — [Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron](https://biopharmsignal.com/news/GPCR/structure-therapeutics-reports-positive-topline-data-from-access-program-for-its-once-daily-oral-small-molecule-glp-1-receptor-agonist-aleniglipron) — Source: Structure Therapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)